COVID Booster Shots For Kids 5-11: What It Means In CT

CONNECTICUT — Connecticut children between the ages of 5 and 11 could soon get a COVID-19 booster shot as cases rise due to omicron subvariants.

The FDA amended the emergency authorization for the Pfizer-BioNTech vaccine Tuesday, authorizing the booster dose for kids between 5-11. It’s the first step in a process that could make the shots available to Connecticut kids later this week.

Under the authorization, the booster can be given at least five months after the kids completed the initial vaccine series.

Connecticut on Monday reported about 10,300 cases over seven days and a positive test rate of 13.41 percent. There are 361 people hospitalized with COVID-19 in state hospitals, which is a 45-patient increase from seven days ago.

Cases among students and staff in Connecticut schools have been increasing in recent weeks. Tere were more than 4,700 cases among students and 1,400 among staff reported between May 5-11, according to the state Department of Public Health. There were about 3,600 student and 1,1182 staff cases in the previous seven-day reporting period.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, a panel of outside experts, is expected to sanction the boosters Thursday, and CDC Director Dr. Rochelle Walensky is expected to give her approval soon after.

At the same time, the federal government is giving away a third round of free COVID-19 tests. The program now offers eight tests to be delivered by the U.S. Postal Service.

Health experts say the new subvariant, known as BA.2.12.1, is particularly worrisome because it is more transmissible than other highly contagious omicron subvariants, and because it’s able to evade antibodies built up from vaccines or previous infections.

Pfizer-BioNTech said last month that a clinical trial involving 140 children showed the booster shot improves children’s immunity both against the original strain of the coronavirus and the omicron variant.

The effectiveness of vaccines wanes over time, and children between 5 and 11 would become the youngest Americans eligible to get the extra level of protection with the approval of the CDC and the Food and Drug Administration.

That leaves children under 5 as the only Americans for whom vaccines are not available. Both Pfizer and Moderna have clinical trials underway to determine the best vaccine regimen for babies, toddlers and preschoolers.

Pfizer paused its application for approval of the vaccine for children under 5 after the FDA asked for more data. Moderna has asked regulators to approve vaccines for young children.

In March, regulators approved a second COVID-19 booster shot for people 50 and older.